{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:20:39Z","timestamp":1762503639655},"reference-count":16,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,5,2]],"date-time":"2008-05-02T00:00:00Z","timestamp":1209686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the outcome and treatment cost of three protocols for childhood non\u2010high risk acute lymphoblastic leukemia (ALL), and evaluate the feasibility of less intensive treatment protocol for low income families.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Two hundred forty\u2010three children were newly diagnosed ALL in a university hospital from May 1999 to August 2006. Three protocols were offered to the patients: China\u201098 protocol, or modified ALLIC BFM2002 protocol, or an in\u2010house Reduced Intensity Protocol (or also known as Economic Protocol).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 243 patients, 19 abandoned treatment, 3 transferred to other hospitals, 48 were high\u2010risk and were treated with the high risk protocol, and 4 had mature B\u2010ALL. A total of 169 cases were enrolled on non\u2010high risk protocols: 46 treated on China\u201098 protocol, 73 on modified ALLIC BFM2002 and 50 from low income families on Economic Protocol. The event\u2010free survival (EFS) at 4 years was 80.4% (95%CI, 68.8\u201392.2%), 83.5% (95%CI, 73.5\u201393.5%), and 72.8% (95%CI, 59.3\u201386.3%) for China\u201098 protocol, modified ALLIC BFM2002, and Economic Protocol respectively. The hospitalization costs (range and median) were significantly different between protocols: US$ 8,700\u201325,500 (12,500), US$ 6,900\u201316,400 (9,900), US$ 3,100\u20136,800 (4,300) for China\u201098 protocol, modified ALLIC BFM2002, and Economic Protocol respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This report from China has systematically reviewed the outcome and costs of protocols for ALL having different dose intensity. The reduced intensity protocol appears to achieve reasonable EFS (72.8% at 4 years) for non\u2010high risk ALL at a much lower cost. This is especially important for low income families in developing countries. Pediatr Blood Cancer 2008;51:204\u2013209. \u00a9 2008 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.21598","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T03:36:30Z","timestamp":1209872190000},"page":"204-209","source":"Crossref","is-referenced-by-count":27,"title":["The comparison of outcome and cost of three protocols for childhood non\u2010high risk acute lymphoblastic leukemia in China"],"prefix":"10.1002","volume":"51","author":[{"given":"Xue\u2010Qun","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi\u2010Yong","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao\u2010Qing","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying\u2010Chuang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li\u2010Bin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,5,2]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14228-6"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-3015"},{"key":"e_1_2_6_4_2","first-page":"490","article-title":"Failure of treatment and protocol compliance in patients with acute lymphoblastic leukemia","volume":"43","author":"Tang JY","year":"2005","journal-title":"Chin J Pediatr"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-011809"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401964"},{"key":"e_1_2_6_7_2","first-page":"1186","article-title":"Treatment reduction in highly selected standard\u2010risk childhood acute lymphoblastic leukemia. The AIEO ALL\u20109501 study","volume":"90","author":"Arico M","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_6_8_2","first-page":"135","article-title":"Asymptotically efficient rank invariant test procedures","author":"Peto R","year":"1972","journal-title":"J R Stat Soc (A)"},{"key":"e_1_2_6_9_2","first-page":"1","article-title":"Analysis of therapeutic effectiveness in 158 childhood acute lymphoblastic leukemia patients treated with ALL\u2010XH\u201099 protocol","volume":"25","author":"Gu LJ","year":"2004","journal-title":"Chin J Hematol"},{"key":"e_1_2_6_10_2","first-page":"158","article-title":"Clinical study on childhood acute lymphoblastic leukemia treated with Rongcheng 98 Protocol","volume":"20","author":"Yu J","year":"2005","journal-title":"Chin J Pract Pediatr"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.10139"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.20.2471"},{"key":"e_1_2_6_13_2","first-page":"340","article-title":"Results of treatment of childhood acute lymphoblastic leukemia according to the Berlin\u2010Moscow\u201091 protocol in1991\u20102000","volume":"48","author":"Miakova NV","year":"2002","journal-title":"Vopr Onkol"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)00112-4"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20989"},{"key":"e_1_2_6_16_2","first-page":"3310","article-title":"Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL\u2010BFM 90","volume":"95","author":"Schrappe M","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.18"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.21598","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.21598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T15:22:35Z","timestamp":1699975355000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.21598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1002\/pbc.21598"],"URL":"https:\/\/doi.org\/10.1002\/pbc.21598","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,2]]}}}